Neurocrine Biosciences, Inc. - Common Stock (NBIX)

Last Price140.88

Change-1.37 (-0.96%)

NASDAQ · Last Trade: Sep 23rd, 3:29 PM EDT

Detailed Quote

Previous Close	142.25
Open	141.97
Bid	140.73
Ask	141.03
Day's Range	139.32 - 142.25
52 Week Range	122.14 - 186.12
Volume	1,165,282
Market Cap	14.10B
PE Ratio (TTM)	30.23
EPS (TTM)	4.7
Dividend & Yield	N/A (N/A)
1 Month Average Volume	1,126,035

About Neurocrine Biosciences, Inc. - Common Stock (NBIX)

Neurocrine Biosciences is a biopharmaceutical company focused on developing innovative treatments for neurological and endocrine diseases. The company conducts research and creates drug therapies aimed at addressing the unmet medical needs of patients suffering from conditions such as movement disorders, psychiatric disorders, and hormonal disorders. Through a combination of scientific expertise and cutting-edge technology, Neurocrine strives to enhance patient outcomes and improve quality of life, while expanding its pipeline of therapeutic options in the field of neuroscience and endocrinology. Read More

News & Press Releases

Neurocrine Maps AI, China and Pipeline Strategy as INGREZZA Faces 2029 Price Hitmarketbeat.com

Neurocrine Biosciences (NASDAQ:NBIX) outlined its commercial growth priorities, pricing considerations and pipeline plans during a Morgan Stanley discussion, with CEO Kyle Gano emphasizing the company’s efforts to diversify beyond its largest product, INGREZZA. Gano said China has become both a com

Via MarketBeat · September 23, 2026

Neurocrine Biosciences (NASDAQ:NBIX): An Affordable Growth Stock With Strong Momentum and Valuationchartmill.com

Via Chartmill · August 29, 2026

Neurocrine Biosciences (NASDAQ:NBIX): A Value Stock With Quality Behind the Discountchartmill.com

Via Chartmill · August 5, 2026

Neurocrine (NBIX) Q2 2026 Earnings Call Transcriptfool.com

Revenue hit $950 million as INGREZZA surged 15% and CRENESSITY grew 20%.

Via The Motley Fool · August 3, 2026

Neurocrine Biosciences (NASDAQ:NBIX): Strong Growth Stock with Technical Breakout Setupchartmill.com

Via Chartmill · July 27, 2026

Neurocrine Biosciences (NASDAQ:NBIX) Screens as a High Growth Stockchartmill.com

Via Chartmill · July 25, 2026

Neurocrine Biosciences (NASDAQ:NBIX) Offers a High Growth Momentum Breakout Setupchartmill.com

Via Chartmill · July 20, 2026

Neurocrine Biosciences (NASDAQ:NBIX) Fits the Growth at a Reasonable Price Mold of Peter Lynch Screeningchartmill.com

Via Chartmill · July 16, 2026

Neurocrine Biosciences Inc (NASDAQ:NBIX) Scores High in Affordable Growth Screenchartmill.com

Via Chartmill · July 11, 2026

Neurocrine Biosciences Q2 Earnings Call Highlightsmarketbeat.com

Neurocrine Biosciences (NASDAQ:NBIX) reported second-quarter 2026 revenue of more than $950 million, nearly 40% higher than a year earlier, as sales of INGREZZA and CRENESSITY continued to grow and the company added a partial-quarter contribution from VYKAT XR following its acquisition of Soleno The

Via MarketBeat · July 31, 2026

Neurocrine (NBIX) Q2 2026 Earnings Call Transcriptfool.com

Revenue hit $950 million as INGREZZA surged 15% and CRENESSITY grew 20%.

Via The Motley Fool · July 30, 2026

Neurocrine Biosciences Inc (NASDAQ:NBIX) Shines in the "Little Book That Makes You Rich" Screenchartmill.com

Via Chartmill · July 4, 2026

Neurocrine Biosciences Inc (NASDAQ:NBIX) Shows Strong Growth and Technical Breakout Setupchartmill.com

Via Chartmill · July 1, 2026

Neurocrine Biosciences (NASDAQ:NBIX) Fits the Profile of a Classic GARP Stock Under the Peter Lynch Frameworkchartmill.com

Via Chartmill · June 24, 2026

Neurocrine Biosciences Inc (NASDAQ:NBIX): A Decent Value Play with Strong Fundamentalschartmill.com

Via Chartmill · June 20, 2026